1.Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gout Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Component Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017-2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter's Five Force Analysis

5. Market Outlook
5.1.Epidemiological Overview of Gout Arthritis
5.2.Pipeline Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Component
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
6.3.1. Colchicine
6.3.2. Antihyperuricemic agents (Urate-Lowering Drugs)
6.3.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
6.3.4. Corticosteroids
6.3.5. Biologic Response Modifiers (Biologics)
6.4. Global Gout Therapeutics Market Attractiveness, by Drug Type

7 Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Global Gout Therapeutics Market Attractiveness, by Distribution Channel

8- Global Gout Therapeutics Market Analysis and Forecast, by Region
8-1. Key Findings
8-2. Global Gout Therapeutics Market Value Forecast, by Region
8-2.1. North America
8-2.2. Europe
8-2.3. Asia Pacific
8-2.4. Latin America
8-2.5. Middle East & Africa
8-3. Global Gout Therapeutics Market Attractiveness, by Country/Region

9. North America Gout Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
9.2.1. Colchicine
9.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
9.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
9.2.4. Corticosteroids
9.2.5. Biologic Response Modifiers (Biologics)
9.3. North America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. North America Gout Therapeutics Market Value Forecast, by Country, 2017-2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Gout Therapeutics Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Gout Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
10.2.1. Colchicine
10.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
10.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
10.2.4. Corticosteroids
10.2.5. Biologic Response Modifiers (Biologics)
10.3. Europe Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Europe Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Gout Therapeutics Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Gout Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Asia Pacific Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
11.2.1. Colchicine
11.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
11.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
11.2.4. Corticosteroids
11.2.5. Biologic Response Modifiers (Biologics)
11.3. Asia Pacific Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4. Asia Pacific Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Gout Therapeutics Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Gout Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Latin America Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
12.2.1. Colchicine
12.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
12.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
12.2.4. Corticosteroids
12.2.5. Biologic Response Modifiers (Biologics)
12.3. Latin America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Pharmacy
12.4. Latin America Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Gout Therapeutics Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Gout Therapeutics Market Value Forecast, by Drug Type, 2017-2027
13.2.1. Colchicine
13.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
13.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
13.2.4. Corticosteroids
13.2.5. Biologic Response Modifiers (Biologics)
13.3. Middle East & Africa Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017-2027
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Online Pharmacy
13.4. Middle East & Africa Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017-2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Company Profiles
14.1.1. Takeda Pharmaceutical Company Limited
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.1.2 Product Portfolio
14.1.1.3. SWOT Analysis
14.1.1.4. Strategic Overview
14.1.1.5. Financial Overview
14.1.2. Teijin Pharma Limited
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.2.2 Product Portfolio
14.1.2.3. SWOT Analysis
14.1.2.4. Strategic Overview
14.1.3. Novartis AG
14.1.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.3.2 Product Portfolio
14.1.3.3. SWOT Analysis
14.1.3.4. Strategic Overview
14.1.3.5. Financial Overview
14.1.4. Mylan N.V.
14.1.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.4.2 Product Portfolio
14.1.4.3. SWOT Analysis
14.1.4.4. Strategic Overview
14.1.4.5. Financial Overview
14.1.5. Horizon Pharma plc.
14.1.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.5.2 Product Portfolio
14.1.5.3. SWOT Analysis
14.1.5.4. Strategic Overview
14.1.5.5. Financial Overview
14.1.6. Teva Pharmaceutical Industries Ltd.
14.1.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.6.2 Product Portfolio
14.1.6.3. SWOT Analysis
14.1.6.4. Strategic Overview
14.1.6.5. Financial Overview
14.1.7 Hikma Pharmaceuticals PLC
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis
14.1.7.4. Strategic Overview
14.1.7.5. Financial Overview
14.1.8- Iroko Pharmaceuticals, LLC
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis
14.1.7.4. Strategic Overview
14.1.9. MERCK & CO., Inc.
14.1.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.9.2 Product Portfolio
14.1.9.3. SWOT Analysis
14.1.9.4. Strategic Overview
14.1.9.5. Financial Overview

List of Tables
Table 01: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2027
Table 2: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
Table 3: Global Gout Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2027
Table 4: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2027
Table 5: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2027
Table 6: North America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel,
2017-2027
Table 7: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 8- Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2027
Table 9: Europe Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
Table 10: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 11: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2027
Table 12: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
Table 13: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 14: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2027
Table 15: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
Table 16: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
Table 17: Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2027
Table 18- Middle East & Africa Gout Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027

List of Figures
Figure 1: Global Gout Therapeutics Market Value (US$ Mn), by Drug Type 2018-(A).
Figure 2: Global Gout Therapeutics Market Share (%), by Distribution Channel, 2017 (A).
Figure 3: Opportunity Map, Drug type.
Figure 4: Opportunity Map, Distribution Channel.
Figure 5: Key Industry Developments.
Figure 6: Global Gout Therapeutics Market Value (US$ Mn) Forecast, 2017-2027
Figure 7: Global Gout Therapeutics Market Value Share, by Drug Type (2018-
Figure 8- Global Gout Therapeutics Market Value Share, by Distribution channel (2018-
Figure 9: Global Gout Therapeutics Market Value Share, by Region (2018-
Figure 10: Global Gout Therapeutics Market Value Split, by Type (2018-
Figure 11: Global Gout Therapeutics Market Value Split, by Region (2018-.
Figure 12: Global Gout Therapeutics Market Value Split, by Distribution Channel (2018-
Figure 13: Global Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018-and 2027
Figure 14: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Antihyperuricemic Agents (Urate-Lowering Drugs), 2017-2027
Figure 15: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDs), 2017-2027
Figure 16: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2017-2027
Figure 17: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Biologics, 2017-2027
Figure 18- Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Colchicine, 2017-2027
Figure 19: Global Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019-2027
Figure 20: Global Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018-and 2027
Figure 21: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2017-2027
Figure 22: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2017-2027
Figure 23: Global Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2017-2027
Figure 24: Global Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 25: Global Gout Therapeutics Market Value Share Analysis, by Region, 2018-and 2027
Figure 26: Global Gout Therapeutics Market Attractiveness Analysis, by Region, 2019?2027
Figure 27: North America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018-and 2027
Figure 28- North America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018-and 2027
Figure 29: North America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018-and 2027
Figure 30: North America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019-2027
Figure 31: North America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 32: North America Gout Therapeutics Market Attractiveness Analysis, by Country, 2019-2027
Figure 33: Europe Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018-and 2027
Figure 34: Europe Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018-and 2027
Figure 35: Europe Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018-and 2027
Figure 36: Europe Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019-2027
Figure 37: Europe Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 38- Europe Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
Figure 39: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018-and 2027
Figure 40: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018-and 2027
Figure 41: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018-and 2027
Figure 42: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019-2027
Figure 43: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 44: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
Figure 45: Latin America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018-and 2027
Figure 46: Latin America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018-and 2027
Figure 47: Latin America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018-and 2027
Figure 48- Latin America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019-2027
Figure 49: Latin America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 50: Latin America Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
Figure 51: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018-and 2027
Figure 52: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Drug Type, 2018-and 2027
Figure 53: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2018-and 2027
Figure 54: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2019-2027
Figure 55: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019-2027
Figure 56: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
Figure 57: Takeda Breakdown of Net Sales, by Region.
Figure 58- Takeda Revenue (US$ Bn) & Y-o-Y Growth (%), 2014-2018-Figure 59: Takeda R&D Expenses (US$ Bn), 2016-2018-Figure 60: Novartis AG Breakdown of Net Sales, by Region, 2018-Figure 61: Novartis AG Breakdown of Net Sales, by Business Segment, 2018-
Figure 62: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015-2018-
Figure 63: Novartis AG R&D Expenses (US$ Mn), 2016-2018-
Figure 64: Teva Pharmaceutical Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2018-
Figure 65: Teva Pharmaceutical R&D Expenses (US$ Bn), 2016-2018-
Figure 66: Teva Pharmaceutical Breakdown of Net Sales, By Region 2018-
Figure 67: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2018-
Figure 68- Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018-Figure 69: Mylan N.V. R&D Expenses (US$ Mn), 2016-2018-Figure 70: Mylan N.V. Breakdown of Net Sales (%), by Region, 2018-
Figure 71: Breakdown of Net Sales (%), by Business Segment, 2018-
Figure 72: Horizon Pharma plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018-
Figure 73: Horizon Pharma plc R&D Expenses (US$ Mn), 2016-2018-
Figure 74: Horizon Pharma plc Breakdown of Net Sales, by Business Segment, 2018-
Figure 75: Horizon Pharma plc Breakdown of Net Sales, by Region, 2018-
Figure 76: Hikma Pharmaceuticals PLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018-Figure 77: Hikma Pharmaceuticals PLC R&D Expenses (US$ Mn), 2016-2018-
Figure 78- Hikma Pharmaceuticals PLC Breakdown of Net Sales, by Business Segment, 2018-Figure 79: Hikma Pharmaceuticals PLC Breakdown of Net Sales, by Region, 2018-
Figure 8-: MERCK & CO., Inc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2018-Figure 8-: MERCK & CO., Inc PLC R&D Expenses (US$ Mn), 2016-2018-
Figure 8- MERCK & CO., Inc PLC Breakdown of Net Sales, by Business Segment, 2018-Figure 8-: MERCK & CO., Inc PLC Breakdown of Net Sales, by Region, 2018-